Home › Compare › SPIDY vs ABBV
SPIDY yields 5.36% · ABBV yields 3.06%● Live data
📍 SPIDY pulled ahead of the other in Year 1
Combined, SPIDY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPIDY + ABBV for your $10,000?
Septeni Holdings Co., Ltd., through its subsidiaries, engages in the digital marketing and media platform businesses in Japan and internationally. The company provides cloud-based CRM and smartphone advertising services. It also cultivates and produces Manga artists and distributes Manga works online. In addition, the company operates ViViViT, a matching-type recruitment platform that matches companies with students aspiring to be IT engineers and web designers; gooddo, a social contribution platform; and Pharmarket, a platform through which it purchases immobile stock from dispensary pharmacies and sells it on to other pharmacies. Further, it provides incubation support services that foster and cultivate new businesses from the initial creation stages. The company was formerly known as Septeni Co., Ltd. and changed its name to Septeni Holdings Co., Ltd. in October 2006. Septeni Holdings Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
Full SPIDY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.